Trial Profile
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 08 Jun 2017 New trial record